{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:55:19Z","timestamp":1791366919517,"version":"4.3.1"},"reference-count":94,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2026,5,13]]},"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:p>\n                    The increasing availability and decreasing costs of DNA sequencing have resulted in the re-grouping of rare, severe paediatric cases of progressive familial intrahepatic cholestasis (PFIC) with more frequent, later-onset cases of cholestasis (eg, intrahepatic cholestasis of pregnancy, benign recurrent intrahepatic cholestasis, low phospholipid-associated cholelithiasis) under the umbrella of genetic cholestasis. The common denominator is the presence of functional variants in the PFIC-associated genes, predominantly in\n                    <jats:italic>ABCB4<\/jats:italic>\n                    ,\n                    <jats:italic>ABCB11<\/jats:italic>\n                    and\n                    <jats:italic>ATP8B1<\/jats:italic>\n                    , which cause PFIC types 1\u20133. Several other congenital diseases such as Alagille syndrome and alpha1-antitrypsin deficiency comprise cholestatic pruritus as frequent symptoms.\n                  <\/jats:p>\n                  <jats:p>With the availability of intestinal bile acid transporter inhibitors (IBATi) as new and efficacious therapeutics for pruritus, the most debilitating symptom of PFIC, it is essential to envision their usefulness for patients with later-onset cholestatic liver disease suffering from pruritus.<\/jats:p>\n                  <jats:p>In this review, we summarise published studies on the genetic makeup of patients with paediatric, juvenile and adult-onset cholestasis, and discuss their findings with respect to genotype-specific treatment with IBATi, ursodeoxycholic acid, or alternative drugs. The aim is to provide an overview of the genetic variants likely to be encountered in future sequencing investigations of patients with cholestatic liver diseases, and how to translate this genetic information into personalised treatment recommendations.<\/jats:p>","DOI":"10.1136\/gutjnl-2025-337027","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:20:19Z","timestamp":1781716819000},"page":"2267-2277","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Use of genetic analysis in adult cholestatic liver disease: lessons from progressive paediatric syndromes and cohort studies"],"prefix":"10.1136","volume":"75","clinical-trial-number":[{"clinical-trial-number":"nct02160782","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Roman","family":"Liebe","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Transplant Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Lammert","sequence":"additional","affiliation":[{"name":"Center for Health Economics Research Hannover (CHERH), Hannover Medical School, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut H","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Transplant Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0113-0777","authenticated-orcid":false,"given":"Marcin","family":"Krawczyk","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Transplant Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2026100702350600000_75.11.2267.1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0398-219"},{"key":"2026100702350600000_75.11.2267.2","doi-asserted-by":"publisher","DOI":"10.1038\/3034"},{"key":"2026100702350600000_75.11.2267.3","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/9.8.1209"},{"key":"2026100702350600000_75.11.2267.4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1089-3261(05)70083-0","article-title":"Benign recurrent intrahepatic cholestasis","volume":"3","author":"Luketic","year":"1999","journal-title":"Clin Liver Dis"},{"key":"2026100702350600000_75.11.2267.5","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jhep.2017.07.004","article-title":"Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants","volume":"67","author":"Dr\u00f6ge","year":"2017","journal-title":"J Hepatol"},{"key":"2026100702350600000_75.11.2267.6","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200402000-00003"},{"key":"2026100702350600000_75.11.2267.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.01.034"},{"key":"2026100702350600000_75.11.2267.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199011293232203"},{"key":"2026100702350600000_75.11.2267.9","doi-asserted-by":"crossref","DOI":"10.1186\/s12920-024-01795-w","article-title":"Whole genome sequencing in clinical practice","volume":"17","author":"Bagger","year":"2024","journal-title":"BMC Med Genomics"},{"key":"2026100702350600000_75.11.2267.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01836-1"},{"key":"2026100702350600000_75.11.2267.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101518","article-title":"Genome-first evaluation with exome sequence and clinical data uncovers underdiagnosed genetic disorders in a large healthcare system","volume":"5","author":"Forrest","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026100702350600000_75.11.2267.12","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad1005"},{"key":"2026100702350600000_75.11.2267.13","doi-asserted-by":"publisher","DOI":"10.1136\/jme-2022-108471"},{"key":"2026100702350600000_75.11.2267.14","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/hep.32364","article-title":"Genomic medicine for liver disease","volume":"76","author":"Zheng","year":"2022","journal-title":"Hepatology"},{"key":"2026100702350600000_75.11.2267.15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S2352-4642(23)00259-6","article-title":"Paediatric research sets new standards for therapy in paediatric and adult cholestasis","volume":"8","author":"Jeyaraj","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"2026100702350600000_75.11.2267.16","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-025-03599-2","article-title":"Genotypes and different clinical variants between children and adults in progressive familial intrahepatic cholestasis: a state-of-the-art review","volume":"20","author":"Vitale","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"2026100702350600000_75.11.2267.17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/a-2122-7674","article-title":"Pediatric and Adult Liver Disease in Alpha-1 Antitrypsin Deficiency","volume":"43","author":"Ruiz","year":"2023","journal-title":"Semin Liver Dis"},{"key":"2026100702350600000_75.11.2267.18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/13543784.2022.2151890","article-title":"Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia","volume":"31","author":"Laue","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"2026100702350600000_75.11.2267.19","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10070-w"},{"key":"2026100702350600000_75.11.2267.20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jpn3.12042","article-title":"Update on the diagnosis and management of neonatal intrahepatic cholestasis caused by citrin deficiency: Expert review on behalf of the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition","volume":"78","author":"Inui","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026100702350600000_75.11.2267.21","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/MPG.0000000000003094","article-title":"Use of a Comprehensive 66-Gene Cholestasis Sequencing Panel in 2171 Cholestatic Infants, Children, and Young Adults","volume":"72","author":"Karpen","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026100702350600000_75.11.2267.22","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.00414","article-title":"Targeted Next-Generation Sequencing in Diagnostic Approach to Monogenic Cholestatic Liver Disorders-Single-Center Experience","volume":"8","author":"Lipi\u0144ski","year":"2020","journal-title":"Front Pediatr"},{"key":"2026100702350600000_75.11.2267.23","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18485","article-title":"Whole-exome sequencing for genetic diagnosis of idiopathic liver injury in children","volume":"28","author":"L\u00fclecio\u011flu","year":"2024","journal-title":"J Cell Mol Med"},{"key":"2026100702350600000_75.11.2267.24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s12072-023-10553-6","article-title":"Diagnostic yield and novel candidate genes by next generation sequencing in 166 children with intrahepatic cholestasis","volume":"18","author":"Zheng","year":"2024","journal-title":"Hepatol Int"},{"key":"2026100702350600000_75.11.2267.25","doi-asserted-by":"crossref","first-page":"113408","DOI":"10.1016\/j.jpeds.2023.113408","article-title":"Combining Panel-Based Next-Generation Sequencing and Exome Sequencing for Genetic Liver Diseases","volume":"258","author":"Chen","year":"2023","journal-title":"J Pediatr"},{"key":"2026100702350600000_75.11.2267.26","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12051169","article-title":"Targeted-Capture Next-Generation Sequencing in Diagnosis Approach of Pediatric Cholestasis","volume":"12","author":"Almes","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"2026100702350600000_75.11.2267.27","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-022-01019-9","article-title":"Clinical implementation of RNA sequencing for Mendelian disease diagnostics","volume":"14","author":"Y\u00e9pez","year":"2022","journal-title":"Genome Med"},{"key":"2026100702350600000_75.11.2267.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100830"},{"key":"2026100702350600000_75.11.2267.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12920-023-01602-y","article-title":"A female of progressive familial intrahepatic cholestasis type 3 caused by heterozygous mutations of ABCB4 gene and her cirrhosis improved after treatment of ursodeoxycholic acid: a case report","volume":"16","author":"Qiao","year":"2023","journal-title":"BMC Med Genomics"},{"key":"2026100702350600000_75.11.2267.30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ajcp\/aqae123","article-title":"Expanding the spectrum of progressive familial intrahepatic cholestasis: A report of 3 cases","volume":"163","author":"Jiao","year":"2025","journal-title":"Am J Clin Pathol"},{"key":"2026100702350600000_75.11.2267.31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.dld.2021.07.003","article-title":"The wide phenotypic and genetic spectrum of ABCB4 gene deficiency: A case series","volume":"54","author":"Falc\u00e3o","year":"2022","journal-title":"Dig Liver Dis"},{"key":"2026100702350600000_75.11.2267.32","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/hep4.2051","article-title":"Clinical phenotype of adult\u2010onset liver disease in patients with variants in ABCB4, ABCB11, and ATP8B1","volume":"6","author":"Nayagam","year":"2022","journal-title":"Hepatol Commun"},{"key":"2026100702350600000_75.11.2267.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-33391-w","article-title":"Rare variant contribution to cholestatic liver disease in a South Asian population in the United Kingdom","volume":"13","author":"Z\u00f6llner","year":"2023","journal-title":"Sci Rep"},{"key":"2026100702350600000_75.11.2267.34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13023-024-03179-w","article-title":"Clinical and genetic study of ABCB4 gene-related cholestatic liver disease in China: children and adults","volume":"19","author":"Cao","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"2026100702350600000_75.11.2267.35","doi-asserted-by":"crossref","first-page":"21540","DOI":"10.1038\/s41598-023-42202-1","article-title":"The diagnostic yield of exome sequencing in liver diseases from a curated gene panel","volume":"13","author":"Kong","year":"2023","journal-title":"Sci Rep"},{"key":"2026100702350600000_75.11.2267.36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104747","article-title":"Advancing diagnosis and management of liver disease in adults through exome sequencing","volume":"95","author":"Zheng","year":"2023","journal-title":"EBioMedicine"},{"key":"2026100702350600000_75.11.2267.37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065823","article-title":"Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis","volume":"24","author":"Vitale","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026100702350600000_75.11.2267.38","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28265"},{"key":"2026100702350600000_75.11.2267.39","doi-asserted-by":"crossref","first-page":"101803","DOI":"10.1016\/j.clinre.2021.101803","article-title":"Acute cholestatic liver injury following carbimazole treatment in a patient with VPS33B haploinsufficiency","volume":"46","author":"Adams","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2026100702350600000_75.11.2267.40","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.35953","article-title":"Heterozygous Inactivation of the Nuclear Receptor PXR\/NR1I2 in a Patient With Anabolic Steroid-Induced Intrahepatic Cholestasis","volume":"16","author":"Liebe","year":"2016","journal-title":"Hepat Mon"},{"key":"2026100702350600000_75.11.2267.41","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2019.01.036","article-title":"Clinical utility of genomic analysis in adults with idiopathic liver disease","volume":"70","author":"Hakim","year":"2019","journal-title":"J Hepatol"},{"key":"2026100702350600000_75.11.2267.42","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000408","article-title":"Genetics of liver disease in adults","volume":"8","author":"Konkwo","year":"2024","journal-title":"Hepatol Commun"},{"key":"2026100702350600000_75.11.2267.43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jhep.2024.04.006","article-title":"EASL Clinical Practice Guidelines on genetic cholestatic liver diseases","volume":"81","author":"Verkade","year":"2024","journal-title":"J Hepatol"},{"key":"2026100702350600000_75.11.2267.44","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ijlh.13747","article-title":"Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely?","volume":"44","author":"Kawata","year":"2022","journal-title":"Int J Lab Hematology"},{"key":"2026100702350600000_75.11.2267.45","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jhep.2023.03.030","article-title":"Hepatology Genome Rounds: An interdisciplinary approach to integrate genomic data into clinical practice","volume":"79","author":"Chung","year":"2023","journal-title":"J Hepatol"},{"key":"2026100702350600000_75.11.2267.46","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jhep.2023.05.049","article-title":"Where does genetic testing fit in the diagnostic pathway of patients with cryptogenic cirrhosis?","volume":"79","author":"Nayagam","year":"2023","journal-title":"J Hepatol"},{"key":"2026100702350600000_75.11.2267.47","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2779"},{"key":"2026100702350600000_75.11.2267.48","doi-asserted-by":"publisher","DOI":"10.1093\/bfgp\/elu025"},{"key":"2026100702350600000_75.11.2267.49","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2023-000554","article-title":"Performance of polygenic risk scores in screening, prediction, and risk stratification: secondary analysis of data in the Polygenic Score Catalog","volume":"2","author":"Hingorani","year":"2023","journal-title":"BMJ Med"},{"key":"2026100702350600000_75.11.2267.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2022.04.009"},{"key":"2026100702350600000_75.11.2267.51","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-017-1212-4","article-title":"The impact of rare and low-frequency genetic variants in common disease","volume":"18","author":"Bomba","year":"2017","journal-title":"Genome Biol"},{"key":"2026100702350600000_75.11.2267.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407934"},{"key":"2026100702350600000_75.11.2267.53","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-306896"},{"key":"2026100702350600000_75.11.2267.54","article-title":"Genotype-phenotype relationships of truncating mutations","volume":"5","author":"Felzen","year":"2023","journal-title":"JHEP Rep"},{"key":"2026100702350600000_75.11.2267.55","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jpn3.12080","article-title":"Clinical outcomes of ABCB4 heterozygosity in infants and children with cholestatic liver disease","volume":"78","author":"Hegarty","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026100702350600000_75.11.2267.56","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s13023-022-02565-6","article-title":"A common variant in the hepatobiliary phospholipid transporter ABCB4 modulates liver injury in PBC but not in PSC: prospective analysis in 867 patients","volume":"17","author":"Kruk","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2026100702350600000_75.11.2267.57","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32437"},{"key":"2026100702350600000_75.11.2267.58","doi-asserted-by":"crossref","first-page":"100844","DOI":"10.1016\/j.jhepr.2023.100844","article-title":"Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy","volume":"5","author":"Gonzales","year":"2023","journal-title":"JHEP Reports"},{"key":"2026100702350600000_75.11.2267.59","doi-asserted-by":"crossref","first-page":"1012825","DOI":"10.3389\/fped.2022.1012825","article-title":"Case Report: A rare case of young adult progressive familial intrahepatic cholestasis-type 3 with a novel heterozygous pathogenic variant of ABCB4","volume":"10","author":"Zhu","year":"2022","journal-title":"Front Pediatr"},{"key":"2026100702350600000_75.11.2267.60","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/apt.13449","article-title":"The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study","volume":"43","author":"Hegade","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026100702350600000_75.11.2267.61","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S2468-1253(24)00080-3","article-title":"Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Miethke","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100702350600000_75.11.2267.62","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S2468-1253(24)00074-8","article-title":"Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"9","author":"Ovchinsky","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100702350600000_75.11.2267.63","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study","volume":"398","author":"Gonzales","year":"2021","journal-title":"Lancet"},{"key":"2026100702350600000_75.11.2267.64","first-page":"71","article-title":"Maralixibat: First Approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026100702350600000_75.11.2267.65","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100702350600000_75.11.2267.66","first-page":"1781","article-title":"Odevixibat: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026100702350600000_75.11.2267.67","doi-asserted-by":"crossref","first-page":"100949","DOI":"10.1016\/j.jhepr.2023.100949","article-title":"Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis","volume":"6","author":"McKiernan","year":"2024","journal-title":"JHEP Rep"},{"key":"2026100702350600000_75.11.2267.68","doi-asserted-by":"crossref","first-page":"101361","DOI":"10.1016\/j.jhepr.2025.101361","article-title":"Comment on opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis","volume":"7","author":"Gonzales","year":"2025","journal-title":"JHEP Reports"},{"key":"2026100702350600000_75.11.2267.69","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1253223"},{"key":"2026100702350600000_75.11.2267.70","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.25542"},{"key":"2026100702350600000_75.11.2267.71","doi-asserted-by":"crossref","unstructured":"Yang Y , Hao C , Jiao T , et al . Osteoarthritis treatment via the GLP-1\u2013mediated gut-joint axis targets intestinal FXR signaling. Science 2025;388. doi:10.1126\/science.adt0548","DOI":"10.1126\/science.adt0548"},{"key":"2026100702350600000_75.11.2267.72","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.bone.2013.03.012","article-title":"Modeling hepatic osteodystrophy in Abcb4 deficient mice","volume":"55","author":"Hochrath","year":"2013","journal-title":"Bone"},{"key":"2026100702350600000_75.11.2267.73","doi-asserted-by":"crossref","unstructured":"Canadian Agency for Drugs and Technologies in Health . Maralixibat (livmarli): indication: for the treatment of cholestatic pruritus in patients with alagille syndrome: reimbursement recommendation; table 4, summary of economic evaluation. 2024. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK604841\/","DOI":"10.51731\/cjht.2024.889"},{"key":"2026100702350600000_75.11.2267.74","unstructured":"Canadian Agency for Drugs and Technologies in Health . Odevixibat (Bylvay): CADTH Reimbursement Recommendation: Indication: The treatment of pruritus in patients aged 6 months or older with progressive familial intrahepatic cholestasis Ottawa (ON). 2024. Available: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38648297"},{"key":"2026100702350600000_75.11.2267.75","unstructured":"Lohse AW . Stellungnahme zur Nutzenbewertung Maralixibat (Neues Anwendungsgebiet: Progressive famili\u00e4re intrahepatische Cholestase (PFIC), \u2265 3 Monate). 2024. Available: https:\/\/www.dgvs.de\/wp-content\/uploads\/2024\/11\/DGVS_Lohse_STN-Maralixibat_WEBSITE_28.11.24.pdf"},{"key":"2026100702350600000_75.11.2267.76","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26018"},{"key":"2026100702350600000_75.11.2267.77","doi-asserted-by":"crossref","first-page":"102358","DOI":"10.1016\/j.clinre.2024.102358","article-title":"PPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old","volume":"48","author":"Tanaka","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2026100702350600000_75.11.2267.78","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/HEP.0000000000000728","article-title":"Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis","volume":"80","author":"Kremer","year":"2024","journal-title":"Hepatology"},{"key":"2026100702350600000_75.11.2267.79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306185"},{"key":"2026100702350600000_75.11.2267.80","doi-asserted-by":"crossref","unstructured":"Rodriguez N , Katzenstein C , O\u2019Kula S , et al . Use of maralixibat in severe and recurrent intrahepatic cholestasis of pregnancy with concurrent benign recurrent intrahepatic cholestasis (BRIC). J Hepatol 2025. doi:10.1016\/j.jhep.2025.05.018","DOI":"10.1016\/j.jhep.2025.05.018"},{"key":"2026100702350600000_75.11.2267.81","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2468-1253(25)00192-X","article-title":"Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Hirschfield","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100702350600000_75.11.2267.82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S2468-1253(25)00200-6","article-title":"Ileal bile acid transporter inhibitors for cholestatic pruritus in primary biliary cholangitis","volume":"11","author":"Lohse","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100702350600000_75.11.2267.83","doi-asserted-by":"crossref","unstructured":"Kowdley K , Shiffman M , Weinstein D . Volixibat leads to improvements in fatigue and sleep for adults with pbc: data from vantage. Abstract 2015. Presented at: AASLD 2025 Liver Meeting; November 7-11, 2025; Washington, DC. Hepatology (Baltimore, Md); 2025 doi:10.1097\/HEP.0000000000001493","DOI":"10.1097\/HEP.0000000000001493"},{"key":"2026100702350600000_75.11.2267.84","doi-asserted-by":"crossref","unstructured":"Levy C , Hirschfield GM , Shiffman M , et al . Efficacy and safety of volixibat, an ibat inhibitor, in patients with primary sclerosing cholangitis and moderate-to-severe pruritus: results of the vistas trial. Abstract LBO-006. Presented at: EASL Congress; May 27-30, 2026; Barcelona, Spain. J Hepatol; 2026:S10\u20131. doi:10.1016\/S0168-8278(26)00310-7","DOI":"10.1016\/S0168-8278(26)00310-7"},{"key":"2026100702350600000_75.11.2267.85","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/hep.32414","article-title":"A hierarchical regulatory network ensures stable albumin transcription under various pathophysiological conditions","volume":"76","author":"Feng","year":"2022","journal-title":"Hepatology"},{"key":"2026100702350600000_75.11.2267.86","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/hep.32119","article-title":"Follistatin-controlled activin-HNF4\u03b1-coagulation factor axis in liver progenitor cells determines outcome of acute liver failure","volume":"75","author":"Lin","year":"2022","journal-title":"Hepatology"},{"key":"2026100702350600000_75.11.2267.87","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.ajhg.2025.03.019","article-title":"Characterization of non-coding variants associated with transcription-factor binding through ATAC-seq-defined footprint QTLs in liver","volume":"112","author":"Dudek","year":"2025","journal-title":"Am J Hum Genet"},{"key":"2026100702350600000_75.11.2267.88","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2020.01.053","article-title":"Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond","volume":"158","author":"Krawczyk","year":"2020","journal-title":"Gastroenterology"},{"key":"2026100702350600000_75.11.2267.89","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100866"},{"key":"2026100702350600000_75.11.2267.90","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15200"},{"key":"2026100702350600000_75.11.2267.91","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jpeds.2018.09.028","article-title":"Panel-Based Next-Generation Sequencing for the Diagnosis of Cholestatic Genetic Liver Diseases: Clinical Utility and Challenges","volume":"205","author":"Chen","year":"2019","journal-title":"J Pediatr"},{"key":"2026100702350600000_75.11.2267.92","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jpeds.2019.04.016","article-title":"Diagnostic Yield of an Algorithm for Neonatal and Infantile Cholestasis Integrating Next-Generation Sequencing","volume":"211","author":"Nicastro","year":"2019","journal-title":"J Pediatr"},{"key":"2026100702350600000_75.11.2267.93","doi-asserted-by":"crossref","DOI":"10.1097\/PG9.0000000000000196","article-title":"Real-life Progression of the Use of a Genetic Panel in to Diagnose Neonatal Cholestasis","volume":"3","author":"Ito","year":"2022","journal-title":"JPGN Rep"},{"key":"2026100702350600000_75.11.2267.94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288907","article-title":"Exome sequencing reveals IFT172 variants in patients with non-syndromic cholestatic liver disease","volume":"18","author":"Ne\u0159oldov\u00e1","year":"2023","journal-title":"PLoS One"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2025-337027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:36:22Z","timestamp":1791365782000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2025-337027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":94,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,10,7]]},"published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1136\/gutjnl-2025-337027"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2025-337027","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}